FDA Will Revise Investigator Disqualification Regs In Response To GAO Report
This article was originally published in The Gray Sheet
FDA will revise its regulations to prevent clinical investigators who are disqualified from running trials for one product type to continue leading studies for other FDA-regulated categories
You may also be interested in...
Radiological health post-market offices moving to OIVD. FDA issues global engagement report. More regulatory news.